https://mindmedicinelaw.com/briefing/oregon-psilocybin-study-impact-on-depression-and-anxiety-20260820-34286The Psychedelic Journalen2026-08-20T22:03:56.908037+00:00Oregon Psilocybin Study: Impact on Depression and Anxietyoregon psilocybin study, depression and anxiety, psychedelic therapy, mental health policy, psilocybin research, public health implications, psilocybin safety, therapeutic potentialhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-program-real-world-study-insights-20260819-34287The Psychedelic Journalen2026-08-20T22:04:15.271224+00:00Oregon's Psilocybin Program: Real-World Study InsightsOregon psilocybin program, psychedelic therapy, regulated psychedelic use, psilocybin study, mental health benefits, policy implications, public health strategy, psilocybin risks, future of psychedelics, psilocybin legislationhttps://mindmedicinelaw.com/briefing/psychedelics-align-brain-activity-with-context-implications-for-research-20260819-34113The Psychedelic Journalen2026-08-20T15:06:11.879184+00:00Psychedelics Align Brain Activity with Context: Implications for Researchpsychedelics, brain activity, therapeutic applications, clinical trials, mental health, neural mechanisms, policy implications, research implications, contextual alignment, psychedelic experienceshttps://mindmedicinelaw.com/briefing/overton-s-fda-nomination-implications-for-psychedelics-20260819-34125The Psychedelic Journalen2026-08-20T15:05:47.296790+00:00Overton's FDA Nomination: Implications for PsychedelicsFDA, Overton, psychedelic research, drug policy, clinical trials, public health, vaccine policy, regulatory change, mental health, innovationhttps://mindmedicinelaw.com/briefing/oregon-s-legal-psilocybin-program-insights-and-implications-20260819-34127The Psychedelic Journalen2026-08-20T15:05:29.437501+00:00Oregon's Legal Psilocybin Program: Insights and ImplicationsOregon psilocybin program, legal psilocybin use, psychedelic therapy, public health policy, psilocybin research, mental health treatment, psilocybin safety, therapeutic potential, regulatory frameworks, psilocybin accessibilityhttps://mindmedicinelaw.com/briefing/va-psilocybin-trial-for-veterans-a-new-frontier-in-mental-health-20260819-34126The Psychedelic Journalen2026-08-20T15:05:11.731650+00:00VA Psilocybin Trial for Veterans: A New Frontier in Mental Healthpsilocybin trial, veterans mental health, treatment-resistant depression, psychedelic research, VA healthcare, mental health policy, clinical trials, neuroplasticity, psychedelic therapies, veterans affairshttps://mindmedicinelaw.com/briefing/esketamine-routes-in-post-op-hyperalgesia-trial-insights-20260818-34426The Psychedelic Journalen2026-08-21T22:06:54.294469+00:00Esketamine Routes in Post-Op Hyperalgesia: Trial Insightsesketamine, postoperative hyperalgesia, elderly patients, pain management, clinical trials, surgical settings, administration routes, opioid alternatives, psychedelic research, neurosciencehttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-brain-dynamics-in-fmri-study-20260818-34424The Psychedelic Journalen2026-08-21T22:06:41.152630+00:00Ketamine's Impact on Brain Dynamics in fMRI Studyketamine, fMRI, rumination, brain dynamics, glutamatergic mechanisms, antidepressant, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/ketamine-therapy-launches-in-aventura-implications-for-florida-20260817-34288The Psychedelic Journalen2026-08-20T22:04:44.199115+00:00Ketamine Therapy Launches in Aventura: Implications for Floridaketamine therapy, Aventura Florida, alternative medicine, mental health treatment, regulatory compliance, clinical oversight, psychedelic research, public health strategies, market dynamicshttps://mindmedicinelaw.com/briefing/ketamine-therapy-s-role-in-mental-health-treatment-expands-20260817-34128The Psychedelic Journalen2026-08-20T15:06:42.259360+00:00Ketamine Therapy's Role in Mental Health Treatment Expandsketamine therapy, mental health treatment, clinical trials, NMDA receptor, depression treatment, FDA guidelines, treatment-resistant depression, psychiatric research, patient care strategies, ketamine riskshttps://mindmedicinelaw.com/briefing/alabama-va-facilities-join-psilocybin-clinical-trials-20260816-34285The Psychedelic Journalen2026-08-20T22:04:29.077161+00:00Alabama VA Facilities Join Psilocybin Clinical Trialspsilocybin trials, Alabama VA facilities, veteran mental health, psychedelic research, PTSD treatment, clinical trials, psychedelic therapy, mental health policy, veteran healthcare, serotonin receptorshttps://mindmedicinelaw.com/briefing/lsd-therapy-research-new-insights-and-implications-20260814-34325The Psychedelic Journalen2026-08-21T15:05:08.261675+00:00LSD Therapy Research: New Insights and ImplicationsLSD therapy, psychedelic research, mental health treatment, clinical trials, serotonin receptors, policy implications, therapeutic benefits, psychedelic-assisted therapies, regulatory changes, adverse effectshttps://mindmedicinelaw.com/briefing/ketamine-and-psychotherapy-new-hope-for-neuropathic-pain-20260813-34129The Psychedelic Journalen2026-08-20T15:06:28.045170+00:00Ketamine and Psychotherapy: New Hope for Neuropathic Painketamine, psychotherapy, neuropathic pain, chronic pain management, psychedelic therapy, clinical trials, FDA regulation, pain treatment innovation